The newest edition highlights innovations that keep ARUP at the forefront of toxicology testing. Also featured: ARUP’s expanded capacity for cytogenetics testing.
ARUP Consult®, a free source of laboratory testing information for clinicians, released several new and updated resources in May.
ARUP Consult, a free source of expert guidance in laboratory testing, has updated resources on autoimmune neurologic diseases, drug detection in newborns, and common variable immunodeficiency.
Mounting evidence suggests that kratom may lead to neonatal abstinence syndrome (NAS) in infants exposed to the substance in utero.
ARUP’S new test is the first of its kind to use two distinct biomarkers to identify in utero exposure to kratom, an herbal supplement that may cause neonatal abstinence syndrome.
ARUP medical directors and scientists will share their research and expertise in areas like lab stewardship, biochemical genetics, and neonatal drug testing at AACC’s 2022 annual meeting in Chicago.
ARUP Consult®, a free source of laboratory testing information for clinicians, released several updated resources in May.
ARUP Consult, a free source of expert guidance in laboratory testing, has released new resources on newborn drug screening and noninvasive prenatal testing.
Dr. Gwen McMillin says ARUP's new therapeutic drug monitoring (TDM) for imatinib has definite patient benefits.
It is silent, but sometimes present. When exposed, a child can be anemic or hyperactive, have a lower IQ or even hearing problems.
Adverse drug reactions cause more than 700,000 ER visits each year, with some 120,000 patients needing to be hospitalized for further treatment, according to the CDC.